Connect your AI

Prime Medicine PRME Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS CommerceSPSC

$4.87M+54.2%

AvePoint, Inc.AVPT

$4.39M+4.3%

Q2 HoldingsQTWO

$45.49M+26.0%

AMN HealthcareAMN

-$4.41M-312%

Rackspace Technology, Inc.RXT

$35.6M+483%

CalixCALX

$675K-80.6%

Other financials

Income statement

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Prime Medicine's increase (decrease) in contract liabilities and current deferred income?: Prime Medicine (PRME) reported increase (decrease) in contract liabilities and current deferred income of -$856K in Q1 2026.
How has Prime Medicine's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Prime Medicine's increase (decrease) in contract liabilities and current deferred income increased by 40.5% year-over-year, from -$1.44M to -$856K.